Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study - Gilead Sciences (NASDAQ:GILD)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced full Phase 3 clinicaltrial results from pivotal Study 102 demonstrating that the Quad, a once-dailysingle tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovirdisoproxil fumarate for the treatment of HIV-1 infection, is non-inferior toAtripla^ after 48weeks of therapy in treatment-naïve adults. Atripla is currently themost-prescribed HIV treatment regimen in the United States. The Study 102findings were presented today in an oral session (Abstract #101) at the 19^thConference on Retroviruses and Opportunistic Infections (CROI 2012) takingplace in Seattle.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!